Chào mừng trở lại
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Tham gia Cointime
Đã có tài khoản?
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Đăng nhập với email
Đăng nhập với
Email của bạn
Đăng ký
Bấm vào liên kết chúng tôi gửi tới để đăng nhập
Nhấp vào liên kết chúng tôi đã gửi tới để đăng ký.
Humanigen
company
About
Humanigen is a biopharmaceutical company that focuses on developing human antibody therapeutics.
- 11 - 50
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $80M
- Industries
- Biopharma,Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2001
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
6
$163M
Humanigen has raised a total of
$163M
in funding over 2 rounds. Their latest funding was raised on
Mar 10, 2021 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 10, 2021 | Post-IPO Debt | $80M | 1 |
Hercules Capital
|
— | Detail |
| Jul 1, 2016 | Post-IPO Equity | $11M | 1 | — | — | Detail |
| Dec 22, 2008 | Series D | $12M | 1 | — | — | Detail |
| Sep 23, 2008 | Series D | $20M | 2 | — | — | Detail |
| Aug 3, 2007 | Series C | $20M | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
4
Humanigen is funded by 4 investors.
Hercules Capital
and Nomis Bay
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Post-IPO Debt |
|
|
— | Post-IPO Equity |
|
|
— | Series D |
|
|
— | Series D |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
